Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...

Sure, who wouldn’t want to lose a few pounds? But what’s really driving Hollywood’s latest trend is the drug’s seemingly miraculous side benefits ...

Research indicates that some individuals can achieve normal blood glucose levels on a keto diet, allowing them to reduce or ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

Palatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...